Seek Returns logo

ASML vs. NVO: A Head-to-Head Stock Comparison

Updated on

Here’s a clear look at ASML and NVO, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.

Company Profile

Both ASML and NVO offer U.S. investors access to foreign companies, with ASML trading as New York Registered Shares and NVO as an American Depositary Receipt (ADR).

SymbolASMLNVO
Company NameASML Holding N.V.Novo Nordisk A/S
CountryNetherlandsDenmark
GICS SectorInformation TechnologyHealth Care
GICS IndustrySemiconductors & Semiconductor EquipmentPharmaceuticals
Market Capitalization296.29 billion USD240.04 billion USD
ExchangeNasdaqGSNYSE
Listing DateMarch 15, 1995April 30, 1981
Security TypeNY Reg ShrsADR

Historical Performance

This chart compares the performance of ASML and NVO by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.

ASML vs. NVO: Growth of a $10,000 investment over the past one year.

Historical Performance at a Glance

SymbolASMLNVO
5-Day Price Return0.27%6.80%
13-Week Price Return-3.37%-19.59%
26-Week Price Return-12.28%-44.66%
52-Week Price Return-21.56%67.26%
Month-to-Date Return4.76%10.67%
Year-to-Date Return-5.36%-44.24%
10-Day Avg. Volume0.45M10.57M
3-Month Avg. Volume0.68M6.69M
3-Month Volatility35.08%64.82%
Beta1.701.51

Profitability

Return on Equity (TTM)

ASML

47.13%

Semiconductors & Semiconductor Equipment Industry

Max
52.74%
Q3
23.49%
Median
11.60%
Q1
3.23%
Min
-20.69%

In the upper quartile for the Semiconductors & Semiconductor Equipment industry, ASML’s Return on Equity of 47.13% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.

NVO

77.86%

Pharmaceuticals Industry

Max
38.59%
Q3
19.84%
Median
11.90%
Q1
5.63%
Min
-9.96%

NVO’s Return on Equity of 77.86% is exceptionally high, placing it well beyond the typical range for the Pharmaceuticals industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.

ASML vs. NVO: A comparison of their Return on Equity (TTM) against their respective Semiconductors & Semiconductor Equipment and Pharmaceuticals industry benchmarks.

Net Profit Margin (TTM)

ASML

29.31%

Semiconductors & Semiconductor Equipment Industry

Max
44.17%
Q3
22.38%
Median
11.95%
Q1
3.21%
Min
-25.16%

A Net Profit Margin of 29.31% places ASML in the upper quartile for the Semiconductors & Semiconductor Equipment industry, signifying strong profitability and more effective cost management than most of its peers.

NVO

35.61%

Pharmaceuticals Industry

Max
34.51%
Q3
17.73%
Median
12.12%
Q1
5.99%
Min
-7.73%

NVO’s Net Profit Margin of 35.61% is exceptionally high, placing it well beyond the typical range for the Pharmaceuticals industry. This demonstrates outstanding operational efficiency and a strong competitive advantage in converting revenue into profit.

ASML vs. NVO: A comparison of their Net Profit Margin (TTM) against their respective Semiconductors & Semiconductor Equipment and Pharmaceuticals industry benchmarks.

Operating Profit Margin (TTM)

ASML

34.90%

Semiconductors & Semiconductor Equipment Industry

Max
58.03%
Q3
27.84%
Median
12.45%
Q1
5.15%
Min
-28.61%

An Operating Profit Margin of 34.90% places ASML in the upper quartile for the Semiconductors & Semiconductor Equipment industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.

NVO

45.78%

Pharmaceuticals Industry

Max
41.53%
Q3
23.00%
Median
16.24%
Q1
9.24%
Min
-6.94%

NVO’s Operating Profit Margin of 45.78% is exceptionally high, placing it well above the typical range for the Pharmaceuticals industry. This demonstrates outstanding efficiency in managing its core operations, which can be a result of strong pricing power or superior cost control.

ASML vs. NVO: A comparison of their Operating Profit Margin (TTM) against their respective Semiconductors & Semiconductor Equipment and Pharmaceuticals industry benchmarks.

Profitability at a Glance

SymbolASMLNVO
Return on Equity (TTM)47.13%77.86%
Return on Assets (TTM)19.27%24.22%
Net Profit Margin (TTM)29.31%35.61%
Operating Profit Margin (TTM)34.90%45.78%
Gross Profit Margin (TTM)52.58%83.95%

Financial Strength

Current Ratio (MRQ)

ASML

1.41

Semiconductors & Semiconductor Equipment Industry

Max
8.42
Q3
4.70
Median
2.75
Q1
2.07
Min
1.04

ASML’s Current Ratio of 1.41 falls into the lower quartile for the Semiconductors & Semiconductor Equipment industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.

NVO

0.78

Pharmaceuticals Industry

Max
4.49
Q3
2.77
Median
1.74
Q1
1.26
Min
0.11

NVO’s Current Ratio of 0.78 falls into the lower quartile for the Pharmaceuticals industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.

ASML vs. NVO: A comparison of their Current Ratio (MRQ) against their respective Semiconductors & Semiconductor Equipment and Pharmaceuticals industry benchmarks.

Debt-to-Equity Ratio (MRQ)

ASML

0.22

Semiconductors & Semiconductor Equipment Industry

Max
1.09
Q3
0.45
Median
0.22
Q1
0.01
Min
0.00

ASML’s Debt-to-Equity Ratio of 0.22 is typical for the Semiconductors & Semiconductor Equipment industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.

NVO

0.59

Pharmaceuticals Industry

Max
2.44
Q3
1.07
Median
0.42
Q1
0.11
Min
0.00

NVO’s Debt-to-Equity Ratio of 0.59 is typical for the Pharmaceuticals industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.

ASML vs. NVO: A comparison of their Debt-to-Equity Ratio (MRQ) against their respective Semiconductors & Semiconductor Equipment and Pharmaceuticals industry benchmarks.

Interest Coverage Ratio (TTM)

ASML

164.15

Semiconductors & Semiconductor Equipment Industry

Max
174.00
Q3
81.10
Median
27.22
Q1
7.28
Min
-4.26

ASML’s Interest Coverage Ratio of 164.15 is in the upper quartile for the Semiconductors & Semiconductor Equipment industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.

NVO

149.07

Pharmaceuticals Industry

Max
103.95
Q3
44.18
Median
9.83
Q1
2.82
Min
-42.71

With an Interest Coverage Ratio of 149.07, NVO demonstrates a superior capacity to service its debt, placing it well above the typical range for the Pharmaceuticals industry. This stems from either robust earnings or a conservative debt load.

ASML vs. NVO: A comparison of their Interest Coverage Ratio (TTM) against their respective Semiconductors & Semiconductor Equipment and Pharmaceuticals industry benchmarks.

Financial Strength at a Glance

SymbolASMLNVO
Current Ratio (MRQ)1.410.78
Quick Ratio (MRQ)0.790.56
Debt-to-Equity Ratio (MRQ)0.220.59
Interest Coverage Ratio (TTM)164.15149.07

Growth

Revenue Growth

ASML vs. NVO: A side-by-side comparison of their Revenue Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

EPS Growth

ASML vs. NVO: A side-by-side comparison of their EPS Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

Dividend

Dividend Yield (TTM)

ASML

1.01%

Semiconductors & Semiconductor Equipment Industry

Max
4.16%
Q3
1.78%
Median
0.74%
Q1
0.00%
Min
0.00%

ASML’s Dividend Yield of 1.01% is consistent with its peers in the Semiconductors & Semiconductor Equipment industry, providing a dividend return that is standard for its sector.

NVO

3.30%

Pharmaceuticals Industry

Max
6.98%
Q3
3.32%
Median
2.13%
Q1
0.14%
Min
0.00%

NVO’s Dividend Yield of 3.30% is consistent with its peers in the Pharmaceuticals industry, providing a dividend return that is standard for its sector.

ASML vs. NVO: A comparison of their Dividend Yield (TTM) against their respective Semiconductors & Semiconductor Equipment and Pharmaceuticals industry benchmarks.

Dividend Payout Ratio (TTM)

ASML

26.57%

Semiconductors & Semiconductor Equipment Industry

Max
196.12%
Q3
87.72%
Median
26.57%
Q1
0.00%
Min
0.00%

ASML’s Dividend Payout Ratio of 26.57% is within the typical range for the Semiconductors & Semiconductor Equipment industry, suggesting a balanced approach between shareholder payouts and company reinvestment.

NVO

61.60%

Pharmaceuticals Industry

Max
165.20%
Q3
90.59%
Median
49.13%
Q1
28.91%
Min
0.00%

NVO’s Dividend Payout Ratio of 61.60% is within the typical range for the Pharmaceuticals industry, suggesting a balanced approach between shareholder payouts and company reinvestment.

ASML vs. NVO: A comparison of their Dividend Payout Ratio (TTM) against their respective Semiconductors & Semiconductor Equipment and Pharmaceuticals industry benchmarks.

Dividend at a Glance

SymbolASMLNVO
Dividend Yield (TTM)1.01%3.30%
Dividend Payout Ratio (TTM)26.57%61.60%

Valuation

Price-to-Earnings Ratio (TTM)

ASML

26.41

Semiconductors & Semiconductor Equipment Industry

Max
109.37
Q3
57.11
Median
28.95
Q1
22.13
Min
11.14

ASML’s P/E Ratio of 26.41 is within the middle range for the Semiconductors & Semiconductor Equipment industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.

NVO

13.91

Pharmaceuticals Industry

Max
42.51
Q3
26.88
Median
19.11
Q1
15.12
Min
0.00

In the lower quartile for the Pharmaceuticals industry, NVO’s P/E Ratio of 13.91 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.

ASML vs. NVO: A comparison of their Price-to-Earnings Ratio (TTM) against their respective Semiconductors & Semiconductor Equipment and Pharmaceuticals industry benchmarks.

Price-to-Sales Ratio (TTM)

ASML

7.74

Semiconductors & Semiconductor Equipment Industry

Max
16.09
Q3
10.10
Median
4.82
Q1
2.60
Min
0.93

ASML’s P/S Ratio of 7.74 aligns with the market consensus for the Semiconductors & Semiconductor Equipment industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.

NVO

4.95

Pharmaceuticals Industry

Max
7.55
Q3
4.54
Median
2.11
Q1
1.52
Min
0.00

NVO’s P/S Ratio of 4.95 is in the upper echelon for the Pharmaceuticals industry. This means the company is valued richly on its revenue stream compared to its peers, suggesting the stock is priced for a high level of future performance.

ASML vs. NVO: A comparison of their Price-to-Sales Ratio (TTM) against their respective Semiconductors & Semiconductor Equipment and Pharmaceuticals industry benchmarks.

Price-to-Book Ratio (MRQ)

ASML

12.39

Semiconductors & Semiconductor Equipment Industry

Max
13.56
Q3
6.75
Median
3.68
Q1
1.89
Min
0.60

ASML’s P/B Ratio of 12.39 is in the upper tier for the Semiconductors & Semiconductor Equipment industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.

NVO

8.87

Pharmaceuticals Industry

Max
9.78
Q3
4.96
Median
2.23
Q1
1.46
Min
0.60

NVO’s P/B Ratio of 8.87 is in the upper tier for the Pharmaceuticals industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.

ASML vs. NVO: A comparison of their Price-to-Book Ratio (MRQ) against their respective Semiconductors & Semiconductor Equipment and Pharmaceuticals industry benchmarks.

Valuation at a Glance

SymbolASMLNVO
Price-to-Earnings Ratio (TTM)26.4113.91
Price-to-Sales Ratio (TTM)7.744.95
Price-to-Book Ratio (MRQ)12.398.87
Price-to-Free Cash Flow Ratio (TTM)26.6723.46